|
業務類別
|
Biotechnology |
|
業務概覽
|
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment. |
| 公司地址
| 12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758 |
| 電話號碼
| +1 737 802-1989 |
| 傳真號碼
| +1 617 995-2410 |
| 公司網頁
| https://www.reintx.com |
| 員工數量
| 10 |
| Dr. James Brian Windsor, PhD |
Chief Executive Officer, President and Director |
美元 506.25K |
26/03/2026 |
| Mr. Timothy M. Cunningham |
Interim Chief Financial Officer and Principal Accounting Officer |
-- |
26/03/2026 |
|
|
| Dr. James Brian Windsor, PhD |
Chief Executive Officer, President and Director |
26/03/2026 |
| Mr. Joseph H. Von Rickenbach |
Chairman of the Board |
26/03/2026 |
| Dr. Reinhard J. Ambros, PhD |
Independent Director |
26/03/2026 |
| Mr. William Carl Fairey, Jr |
Independent Director |
26/03/2026 |
| Mr. Alan A. Musso |
Independent Director |
26/03/2026 |
|
|
|
|
